- Home
- GB vs SPRY Comparison
GB vs SPRY Comparison
Compare GB & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GB
- SPRY
- Stock Information
- Founded
- GB 1980
- SPRY 2015
- Country
- GB Switzerland
- SPRY United States
- Employees
- GB N/A
- SPRY N/A
- Industry
- GB EDP Services
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- GB Technology
- SPRY Health Care
- Exchange
- GB Nasdaq
- SPRY Nasdaq
- Market Cap
- GB 1.5B
- SPRY 1.8B
- IPO Year
- GB N/A
- SPRY N/A
- Fundamental
- Price
- GB $7.40
- SPRY $17.18
- Analyst Decision
- GB Buy
- SPRY Strong Buy
- Analyst Count
- GB 1
- SPRY 4
- Target Price
- GB $6.00
- SPRY $28.75
- AVG Volume (30 Days)
- GB 31.8K
- SPRY 1.3M
- Earning Date
- GB 08-27-2025
- SPRY 08-12-2025
- Dividend Yield
- GB N/A
- SPRY N/A
- EPS Growth
- GB 483.33
- SPRY N/A
- EPS
- GB 0.38
- SPRY N/A
- Revenue
- GB $548,939,689.00
- SPRY $97,122,000.00
- Revenue This Year
- GB $15.17
- SPRY N/A
- Revenue Next Year
- GB $6.50
- SPRY $170.64
- P/E Ratio
- GB $19.51
- SPRY N/A
- Revenue Growth
- GB 20.26
- SPRY 971120.00
- 52 Week Low
- GB $4.29
- SPRY $8.91
- 52 Week High
- GB $8.00
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- GB 50.95
- SPRY 48.47
- Support Level
- GB $7.37
- SPRY $17.70
- Resistance Level
- GB $7.41
- SPRY $18.63
- Average True Range (ATR)
- GB 0.02
- SPRY 0.64
- MACD
- GB 0.01
- SPRY -0.16
- Stochastic Oscillator
- GB 74.03
- SPRY 7.08
About GB Global Blue Group Holding AG
Global Blue Group Holding AG offers a seamless shopping and payment journey for tourists and also provides a wide range of Added-Value Payment Solutions for all the stakeholders involved, including retailers and international shoppers. The company connect thousands of retailers, acquirers, and hotels with nearly 80 million consumers across more than 50 countries, in three industries: Tax Free Shopping, Payments and Post-Purchase solutions.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.